Status and phase
Conditions
Treatments
About
This is a multi-center open-label proof-of-concept study consisting of two parts: PART A - a phase I dose-finding study (3 + 3 classical design) evaluating the RP2D of afatinib in combination with selumetinib in KRASm NSCLC; and PART B - a randomized phase II study investigating the progression free survival and safety of selumetinib/afatinib combination therapy compared to standard of care chemotherapy in KRASm NSCLC.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
320 participants in 2 patient groups
Loading...
Central trial contact
F Opdam, MD, PhD; S huijberts, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal